Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M. Lee CK, et al. Among authors: pfisterer j. Br J Cancer. 2011 Oct 11;105(8):1144-50. doi: 10.1038/bjc.2011.364. Epub 2011 Sep 13. Br J Cancer. 2011. PMID: 21915127 Free PMC article.
CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial.
Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E. Alexandre J, et al. Among authors: pfisterer j. Br J Cancer. 2012 Feb 14;106(4):633-7. doi: 10.1038/bjc.2011.593. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240800 Free PMC article. Clinical Trial.
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M. Lee CK, et al. Among authors: pfisterer j. Ann Oncol. 2013 Apr;24(4):937-43. doi: 10.1093/annonc/mds538. Epub 2012 Oct 26. Ann Oncol. 2013. PMID: 23104722 Free article.
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.
Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, Vergote IB, Gonzalez-Martin A, Alberts DS, Plante M, Torri V, Ledermann JA. Raja FA, et al. Among authors: pfisterer j. Ann Oncol. 2013 Dec;24(12):3028-34. doi: 10.1093/annonc/mdt406. Epub 2013 Nov 4. Ann Oncol. 2013. PMID: 24190964 Free article. Review.
The role of surgery in recurrent ovarian cancer.
Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Bois A; AGO Ovarian Committee; AGO Ovarian Cancer Study Group (AGO-OVAR). Pfisterer J, et al. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:195-8. doi: 10.1111/j.1525-1438.2005.00430.x. Int J Gynecol Cancer. 2005. PMID: 16343230 Free article.
The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy.
Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, Ray-Coquard I, Sehouli J, Harter P, du Bois A; AGO and GINECO study group. Hanker LC, et al. Among authors: pfisterer j. Ann Oncol. 2012 Oct;23(10):2605-2612. doi: 10.1093/annonc/mds203. Epub 2012 Aug 21. Ann Oncol. 2012. PMID: 22910840 Free article. Clinical Trial.
204 results